Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI
Latest Information Update: 08 Mar 2022
At a glance
- Drugs Dalbavancin (Primary) ; Daptomycin; Teicoplanin; Vancomycin
- Indications Bacterial infections; Cellulitis; Erysipelas; Skin infections; Soft tissue infections; Wound infections
- Focus Therapeutic Use
- Acronyms REDS
Most Recent Events
- 12 May 2021 Status changed from recruiting to completed.
- 31 Jul 2020 Status changed from not yet recruiting to recruiting.
- 11 Mar 2020 New trial record